Press Releases


Sengenics Partners with the Foundation for the National Institutes of Health Biomarkers Consortium to Advance High-Impact Autoantibody Biomarker Discovery for Development of Diagnostics, Companion Diagnostics and Therapeutics

SINGAPORE, 11 July 2019 – Sengenics, the functional proteomics company, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium. As a member of the consortium, Sengenics aims to further accelerate the identification


Read More »


CollabRx, Sengenics Partner on Cancer Diagnostics

CollabRx today announced a deal with Sengenics to incorporate each other’s products into molecular diagnostics tests and reports aimed at cancer.   Under the terms of the agreement, Sengenics will integrate CollabRx’s interpretive content resources into its cancer exome sequencing


Read More »

FEATURED PRODUCTS

IMMUNOME
Protein Array

High-throughput
sero-profiling platform

CTA
Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Custom
Protein Array

Flexible format for
high-throughput screening

2008 – 2019 © Sengenics All rights reserved 

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X